Name (Synonyms) | Correlation | |
---|---|---|
drug1098 | Fecal Microbiota Therapy (FMT) Wiki | 1.00 |
drug919 | Double-Blind NT-I7 Wiki | 1.00 |
drug2122 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The main purposes of this study is to determine the following in participants with mild coronavirus disease 2019 (COVID-19): - Safety of a single dose of NT-I7 - The immunological effects of NT-I7 on peripheral lymphocyte counts in COVID-19 patients.
Description: Assessment of the number and severity of AEs possibly, probably, or definitely related to study drug evaluated at 7 and 30 days.
Measure: Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion Time: Up to approximately 30 daysDescription: Assessment of the trajectory of ALC, CD4, CD8, NK, B, and MAIT cells measured at days 7, 14 and 30 after administration of NT-I7 or placebo compared to baseline values.
Measure: Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients. Time: Up to approximately 30 days